• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Mémoire de Maîtrise
DOI
https://doi.org/10.11606/D.42.2018.tde-30012018-101101
Document
Auteur
Nom complet
Jennifer Eliana Montoya Neyra
Unité de l'USP
Domain de Connaissance
Date de Soutenance
Editeur
São Paulo, 2017
Directeur
Jury
Belizario, Jose Ernesto (Président)
Malpartida, Humberto Miguel Garay
Santelli, Glaucia Maria Machado
Weinlich, Ricardo
Titre en portugais
Modulação dos efeitos citotóxicos dos vemurafenibe pela cloroquina em células de melanoma maligno G-361: papel da dermicidina.
Mots-clés en portugais
Autofagia
BRAF
Cloroquina
Melanoma
Senescência
Vemurafenibe
Resumé en portugais
Neste estudo foram avaliados os efeitos farmacológicos do vemurafenibe (inibidor BRAFV600E) e da cloroquina (inibidor de autofagia) na viabilidade celular e crescimento tumoral das sublinhagens de melanoma:G361 pLKO que expressa dermicidina e G361 IBC I com silenciamento da expressão. As células G-361 responderam a vemurafenibe (2 μM) e cloroquina (100 μM), isoladamente ou combinadas, com aumento apoptose, e redução das taxas de senescência. Vemurafenibe (50 mg/kg / 21 dias) inibiu o crescimento tumoral em camundongos imunodeficientes independente da expressão da DCD. A combinação com Cloroquina (30 mg/kg) a cada 24 horas, acelerou, enquanto a cada 72 horas, reduziu o crescimento tumoral. Os tumores apresentaram alterações morfológicas e núcleos atípicos; e não expressaram os marcadores S100, HMB-45, Mela-A ou citoqueratinas. Este trabalho confirmar a eficácia do vemurafenibe e sugere o potencial adjuvante da cloroquina no tratamento de melanomas. O estudo também confirma o papel da dermcidina como oncogne e fator de crescimento de células de melanoma maligno.
Titre en anglais
Modulation of cytotoxic effects of vemurafenib by chloroquine in malignant melanoma cells G-361: role of dermcidin.
Mots-clés en anglais
Apoptosis
Autophagy
BRAF
Chloroquine
Dermcidin
Melanoma
Senescence
Vemurafenib
Resumé en anglais
In this study we evaluated the pharmacological effects of vemurafenib ( inhibitor BRAFV600E) and chloroquine (autophagy inhibitor) in cell viability and tumor growth of two melanoma cell lines identified as G-361 pLKO, which expresses dermcidin, and G361 IBC I which silenced DCD expression. G-361 melanoma cells responded to vemurafenib (1-2 μM) and chloroquine (50-100 μM) alone or combined, with increased apoptosis rates, while decreasing senescent cells. Vemurafenib (50 mg/kg / 21 days) inhibited melanoma growth in immunodeficient mice independent of dermicidin. Chloroquine (30 mg/kg) in combination with vemurafenib, accelerated (at 24 hour interval), and reduced (at 72 hours interval), melanoma growth. Tumor tissues showed atypical cell morphology and nuclear histological patterns and melanocytic differentiation biomarkers S100, HMB-45, Melan-A or pancytokeratins were not. This work confirms the efficacy of vemurafenib and suggests potential adjuvant effect of chloroquine. It also confirms the role of dermcidin as growth factor and oncogene for melanoma cells.
 
AVERTISSEMENT - Regarde ce document est soumise à votre acceptation des conditions d'utilisation suivantes:
Ce document est uniquement à des fins privées pour la recherche et l'enseignement. Reproduction à des fins commerciales est interdite. Cette droits couvrent l'ensemble des données sur ce document ainsi que son contenu. Toute utilisation ou de copie de ce document, en totalité ou en partie, doit inclure le nom de l'auteur.
Date de Publication
2018-01-31
 
AVERTISSEMENT: Apprenez ce que sont des œvres dérivées cliquant ici.
Tous droits de la thèse/dissertation appartiennent aux auteurs
CeTI-SC/STI
Bibliothèque Numérique de Thèses et Mémoires de l'USP. Copyright © 2001-2024. Tous droits réservés.